Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 11 Dec 2017
At a glance
- Drugs Pembrolizumab (Primary) ; SGN LIV1A (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Seattle Genetics
- 05 Dec 2017 Planned initiation date changed from 1 Nov 2017 to 1 Jan 2018.
- 13 Oct 2017 New trial record
- 11 Oct 2017 Status changed from planning to not yet recruiting.